RELMADA THERAPEUTICS, INC. Related Parties Amount in Cost of Sales
RELMADA THERAPEUTICS, INC. (RLMD) reported Related Parties Amount in Cost of Sales of $13.15 million for the 0-month period ending 2022-08-08, per its 10-Q filed 2022-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RelatedPartiesAmountInCostOfSales · last filed 2022-11-10
- RELMADA THERAPEUTICS, INC. related parties amount in cost of sales for the quarter ending 2022-06-30 was $13.15M.
- RELMADA THERAPEUTICS, INC. related parties amount in cost of sales for the quarter ending 2022-03-31 was $29.58M.
| Period end | Related Parties Amount in Cost of Sales 0 month | Related Parties Amount in Cost of Sales 3 month | Related Parties Amount in Cost of Sales 6 month |
|---|---|---|---|
| 2022-08-08 | $13.15M 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $13.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $42.73M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $29.58M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |